JKJakub Kalisiak

Jakub Kalisiak

*This is an algorithmically generated author record based on publicly available information.

Jakub Kalisiak has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development of Hashimoto's disease in patients with vitiligo

    by Jakub Paprocki, Anna Mataczyńska, Michał Paprocki, Mateusz Dobosz, Klaudia Arciszewska, Anna Szpernalowska, Vimbisoyashe Ivy Matshaba, Karolina Mrugała, Martyna Choinka, Jakub Kalisiak

    The aim of this paper is to review the available scientific literature on the relationship between vitiligo and the development of Hashimoto's disease, with particular emphasis on possible pathogenetic mechanisms and clinical implications of this correlation. The relationship between vitiligo and thyroid diseases, especially Hashimoto's disease, has intrigued researchers for years. Numerous clinical observations suggested that patients with vitiligo more often struggle with thyroid problems, but only extensive epidemiological studies allowed for a precise estimate of the scale of this phenomenon.

  • Open Access

    Lignocaine in Migraine Treatment: A Comprehensive Review

    by Jakub Kalisiak, Max Tschuschke, Martyna Choinka, Mikołaj Lorenz, Jędrzej Lewandowski, Agata Konopka, Zuzanna Szczepaniak, Natalia Wdowiak, Małgorzata Komarów, Dominika Karasińska

    Introduction: Migraine is a prevalent and debilitating neurological disorder characterized by recurrent headaches and associated symptoms such as nausea, photophobia, and phonophobia. While conventional treatments exist, a significant subset of patients suffers from refractory migraines, prompting the exploration of alternative therapies like lignocaine. Purpose of the work: This review examines the mechanisms by which lignocaine modulatespain and underscores the potential of lignocaine as a therapeutic option for refractory migraines, while also highlighting the need for continued research to refine its clinical application. Materials and methods: A comprehensive analysis of research papers available on PubMed, Google Scholar, Web of Science, Embase and Scopus was undertaken using the searchterms encompassing the following keywords: chronic migraine / lignocaine migraine / migraine treatment/ migraine pain mechanism / migraine chronic pain mechanism / lignocaine and ketamine migraine / lignocaine adverse effects / lignocaine safety / refractory migraine. Results: Lignocainehas shown promise in alleviating both acute and chronic migraine pain. However, its use requires careful patient selection and monitoring due to potential side effects, such as cardiac and central nervous system toxicity. Despite these risks, the favorable safety profile and efficacy of lignocaine make it a valuable option in migraine management. Future research should focus on optimizing dosing protocols, evaluating long-term outcomes, and identifying biomarkers to guide patient selection.

  • Open Access

    What Sets Uveal Melanoma Apart, and How Can We Address It? A Comprehensive Review of Pathophysiology, Diagnosis and Treatment

    by Karina Lissak, Zuzanna Szczepaniak, Agata Konopka, Natalia Wdowiak, Martyna Choinka, Małgorzata Komarów, Dominika Karasińska, Jakub Kalisiak, Mateusz Koralewicz, Milena Orzeł, et al.

    Uveal melanoma (UM) is a serious condition requiring immediate medical attention. It is the most common primary intraocular cancer in adults, with an incidence of around 5.2 cases per million people annually. Nearly half of UM patients develop metastatic disease, most often affecting the liver. UM refers to any malignant tumor arising from melanocytes in the uveal tract, which includes the iris, ciliary body, and choroid. Treatment options for UM depend on several factors, including tumor size, location, and the patient's overall health. These options may include radiation therapy, surgery, laser treatments, targeted therapies, and immunotherapy. UM is often described as an immune-privileged tumor, with a distinct immune profile compared to cutaneous melanoma (CM). This article aims to highlight the unique characteristics and challenges associated with this rare form of melanoma. By providing detailed information, the article seeks to enhance understanding and management of this rare form of melanoma.


  • Open Access

    Human Immunodeficiency Virus - a Review of the clinical aspects and detection of the infection

    by Martyna Choinka, Agata Konopka, Natalia Wdowiak, Zuzanna Szczepaniak, Jakub Kalisiak, Anna Szpernalowska, Vimbisoyashe Ivy Matshaba, Karolina Mrugała

    Introduction: Currently, many people are infected with the human immunodeficiency virus (HIV). Transmission is primarily through sexual contact, with additional routes including mother-infant exposure to needles and needle sharing. Since the HIV/AIDS pandemic was first identified in 1981, more than 75 million people have been infected. Numerous new cases continue to be reported, and infection can become the starting point for the development of HIV. Clinical manifestations include acute retroviral syndrome, opportunistic infections, and dermatological, neuromuscular, and other complications. Despite advances in antiretroviral therapy (ART), challenges remain, including drug resistance, opportunistic infections, and persistent HIV reservoirs in some cell types. Early and accurate diagnosis is essential, and recommended testing protocols include fourth-generation serological tests and point-of-care (POC) testing. ART, which includes combinations of antiretroviral drugs, is the standard treatment, and ongoing research into gene therapy shows promise for the future. Purpose of the work: The aim of this study is to review and characterize the clinical aspects and detection of human immunodeficiency virus infection. Materials and methods: A comprehensive analysis of research papers available on PubMed, Google Scholar, Web of Science, Embase and Scopus was undertaken using the searchterms encompassing the following keywords: HIV, human immunodeficiency virus, ART, HIV manifestation, HIV detection, HIV diagnosis, HIV treatment.

  • Open Access

    Autism Spectrum Disorder: Latest Advances in Treatment

    by Anna Szpernalowska, Vimbisoyashe Ivy Matshaba, Karolina Mrugała, Martyna Choinka, Jakub Kalisiak, Anna Mataczyńska, Michał Paprocki

    Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition marked by deficits in social communication and the presence of restricted, repetitive behaviours. Despite the global prevalence of ASD, its diagnosis and treatment remain challenging due to the absence of specific biomarkers and the heterogeneity of symptoms. ASD is incurable and current management options aim to minimize the symptoms and maximize the patients’ ability to function. There is no one standardized treatment for ASD at present, recommended medical interventions involve various therapies which include cognitive behavioral therapy alongside additional personalized pharmacological symptomatic treatments. New approach for ASD management includes sensory integration therapy (SIT) as well as dietary interventions, like gluten-free, casein-free and ketogenic diets. Other innovative treatment strategies are targeted at gut microbiome and include probiotic treatment and fecal microbiota transplant. In this review possible genetic variants associated with ASD are discussed as well as their influence on the manifestation and management of clinical symptoms. For a better understanding on how genetic variables impact drug effectiveness in individuals and the importance of pharmacogenetics in ASD. This paper aims to explore the available and possible treatment options as well the genetic components associated with ASD. In summary, this paper reviews the current and emerging treatment options for ASD.


  • Open Access

    Congenital Adrenal Hyperplasia: A Review of Current Knowledge and Future Directions

    by Zuzanna Szczepaniak, Agata Konopka, Natalia Wdowiak, Karina Lissak, Małgorzata Komarów, Martyna Choinka, Dominika Karasińska, Jakub Kalisiak

    Introduction: Congenital adrenal hyperplasia (CAH) is a group of diseases in which genetic defects occur that disturb the synthesis of cortisol. The most common variant of CAH (95%-99%) is caused by 21-hydroxylase deficiency as a result of mutations in the CYP21A2 gene and is one of the most common monogenic diseases. CAH is characterized by androgen overproduction along with variable degrees of cortisol and aldosterone deficiency. Age at diagnosis can provide some information about the underlying mutations, with those diagnosed at birth/early infancy being at greater risk of developing serious enzyme defects. Classic and non-classical forms of this disorder have been described in the literature. CAH diagnosis is based on the clinical presentation, hormonal panel, Adrenocorticotropic Hormone (ACTH) stimulation test, and genetic testing. The main goals of treatment for congenital adrenal hyperplasia are glucocorticoid/mineralcorticoid supplementation, control of high adrenal androgen levels, fertility control, genetic counseling, and optimization of patients’ quality of life. Purpose of the work: This study aims to review and characterize the clinical and pathophysiological aspects of congenital adrenal hyperplasia. Materials and methods: A comprehensive analysis of research papers available on PubMed, Google Scholar, Web of Science, Embase and Scopus was undertaken using the searchterms encompassing the following keywords: congenital adrenal hyperplasia, 21-hydroxylase deficiency, CYP21A2 Results: Congenital adrenal hyperplasia is a heterogeneous group of genetic disorders that can lead to serious and even fatal complications in the form of adrenal crisis. Therefore, screening tests and early diagnosis are crucial and can save the lives of newborns. Treatment should be individualized and allow patients to achieve normal growth, sexual development, fertility and a better quality of life.


  • Open Access

    Novel methods of treating atopic dermatitis

    by Martyna Choinka, Małgorzata Komarów, Natalia Wdowiak, Karina Lissak, Zuzanna Szczepaniak, Agata Konopka, Jakub Kalisiak, Dominika Karasińska

    Atopic dermatitis is a long-term inflammatory skin disease caused by factors such as skin barrier dysfunction and immune system dysregulation . Currently, the first-line treatment for atopic dermatitis involves the use of topical glucocorticosteroids; however, this treatment is associated with many side effects. Therefore the need of finding new methods of treatment arises. Objective: The objective of this study is to gather and analyze literature on new methods of treating atopic dermatitis. Materials and methods: The review was based on the analysis of materials collected in the database, PubMed, Google Scholar, Web of Science, Embaseand, Scopus, books and other scientific articles.

  • Open Access

    Comprehensive Review of TORCH Syndrome: Characterization and Prevention Strategies

    by Agata Konopka, Zuzanna Szczepaniak, Natalia Wdowiak, Karina Lissak, Małgorzata Komarów, Martyna Choinka, Dominika Karasińska, Jakub Kalisiak

    Introduction: TORCH syndrome refers to a group of symptoms caused by congenital infections with teratogenic pathogens, including Toxoplasma gondii, Varicella, Treponema pallidum, Parvovirus B19, Rubella, Cytomegalovirus (CMV), and Herpes simplex virus (HSV). It can also encompass infections like HIV, Zika virus (ZIKV), hepatitis B, and SARS-CoV-2. These pathogens can pass through the placenta, overcoming various placental barriers. Infections during pregnancy can result in severe consequences for both the fetus and the mother. Common symptoms in newborns include low birth weight, rashes, hepatosplenomegaly, cardiac anomalies, jaundice, chorioretinitis, and microcephaly, with 2% to 3% of congenital anomalies attributed to perinatal infections. The incidence of these infections varies globally. Purpose of the work: This study aims to review and characterize TORCH syndrome and the prevention of TORCH infections. Materials and methods: A comprehensive analysis of research papers available on PubMed, Google Scholar, Web of Science, Embase and Scopus was undertaken using the searchterms encompassing the following keywords: TORCH syndrome / infections during pregnancy / perinatal infections / Toxoplasmosis / Rubella / CMV infection / Herpes Simplex Virus infection / Parvovirus B19 / Treponema pallidum / vaccinations before and during pregnancy / maternal nutrition. Results: TORCH syndrome is a significant issue causing congenital diseases, premature births, and intrauterine deaths, impacting babies throughout their lives. Most complications can be prevented with proper prophylaxis and early treatment. Increasing awareness and providing education for women from preconception through the early postnatal period is essential. Addressing TORCH syndrome remains a major medical challenge, but improving management offers hope for better outcomes.